Tag: #glp1

23andMe study finds common gene variants modestly affect weight loss and nausea on GLP‑1 drugs

A Nature paper by 23andMe links common DNA variants to small differences in weight loss and nausea on GLP‑1 drugs; the company released a consumer report.

#genetics, #glp1, #23andme, #weightloss, #semaglutide

Tirzepatide shows broader heart-and-kidney edge over dulaglutide in diabetes trial analysis

A post hoc look at the 13,000-patient SURPASS-CVOT trial finds fewer combined heart and kidney events with tirzepatide than dulaglutide.

#diabetes, #cardiology, #glp1, #kidneydisease, #clinicaltrials

Lilly’s daily GLP-1 pill beats Novo’s oral semaglutide in diabetes trial, but side effects drive more dropouts

A Phase 3 head-to-head study finds Lilly’s orforglipron lowered A1c and weight more than Rybelsus, with higher quit rates.

#diabetes, #glp1, #weightloss, #pharma, #clinicaltrials

FDA-Approved Wegovy Pill Rolls Out Nationwide, Offering Daily Alternative to Weekly Injections

Novo Nordisk says its once-daily Wegovy tablet is now widely available in the U.S., with lower self-pay prices but strict dosing rules and coverage gaps.

#wegovy, #glp1, #obesity, #cardiovascular, #fda